|Bid||1,664.00 x 16300|
|Ask||1,666.00 x 34600|
|Day's Range||1,643.00 - 1,676.80|
|52 Week Range||1,573.00 - 2,703.00|
|PE Ratio (TTM)||25.17|
|Earnings Date||Aug 17, 2017|
|Dividend & Yield||0.22 (0.87%)|
|1y Target Est||25.92|
Shares in Hikma Pharmaceuticals fell 7 per cent in early trading on Friday after it cut sales forecasts following the US's decision last week to deny regulatory approval for its main pipeline drug. The ...
Hikma Pharmaceuticals Plc lowered its full-year revenue forecast on Friday to reflect a delay in the launch of its generic asthma drug amid pricing pressures in the United States, sending its shares down to a three-year low. Earlier this month, the drugmaker said U.S. regulators decided not to approve its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair, citing "major" issues with the application. The company, which makes and markets branded and non-branded generic and injectable drugs, now expects full-year revenue to be in the range of $2 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion.
Hikma Pharmaceuticals lowered its full year revenue guidance Friday after the U.S. Food & Drug Administration expressed concern over its generic Advair Diskus product.